Clinical trials: Olanzapine
Bipolar Disorder
Olanzapine/Fluoxetine Combination Versus Comparator in the Treatment of Bipolar I Depression
The purpose of this study is to assess olanzapine/fluoxetine combination and lamotrigine comparative efficacy, safety and tolerability in acute and longer term treatment of bipolar depression.
- Trial name
- NCT00485771
- Testing
- Olanzapine, Fluoxetine, Lamotrigine
- Where
- United States
- Volunteers
- 403 people
- Sponsor
- Eli Lilly and Company
Misuse, Opioid
Effect of Olanzapine on Opioid Craving and Misuse Among Patients Receiving Opioids for Cancer-related Pain: A Pilot Double-Blind, Randomized Control Trial
To learn about the effectiveness of taking the antipsychotic medication olanzapine to help lower opioid craving.
- Trial name
- NCT06200181
- Testing
- Olanzapine
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- M.D. Anderson Cancer Center
Schizophrenia, Schizoaffective Disorder
A Trial to Explore Acceptance and Performance of Using a Digital Medicine System With Healthcare Professionals and Adults With Schizophrenia, Schizoaffective Disorder, or First Episode Psychosis on an Oral Atypical Antipsychotic
Digital medicine systems (DMS) have been designed to assist individuals with the management of their daily health, wellness, and medication use.
- Conditions
- Schizophrenia, Schizoaffective Disorder, First Episode Psychosis
- Trial name
- NCT03568500
- Testing
- Digital Medicine System, Aripiprazole, Olanzapine
- Where
- 5 sites in United Kingdom
- Volunteers
- 44 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Healthy
Fasting Study of Olanzapine Tablets 5 mg and Zyprexa® Tablets 5 mg
The objective of this study was to investigate the bioequivalence of Mylan's olanzapine 5 mg tablets to Eli Lilly's Zyprexa® 5 mg tablets following a single, oral 5 mg (1 x 5 mg) dose administered under fasting conditions.
- Trial name
- NCT00648921
- Testing
- Olanzapine Tablets 5 mg, Zyprexa® Tablets 5 mg
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Mylan Pharmaceuticals Inc
Pharmacokinetics
Fasted Bioequivalence Study of 2 Olanzapine Film-coated Tablets, 5 mg, in Healthy, Adult Male and Female Subjects.
This study was designed to assess the bioequivalence of Olanzapine tablets of two different manufacturers and to investigate the safety and tolerability of Olanzapine tablets of two different manufacturers.
- Trial name
- NCT05123976
- Testing
- Olanzapine film-coated tablets 5 mg (JSC Farmak, Ukraine), Zyprexa® coated tablets 5 mg (Eli Lilly, Nederland B V)
- Where
- Czechia
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Joint Stock Company "Farmak"
Schizophrenia; Psychosis, Metabolic Syndrome
Adjunctive Use of Fute (Flupentixol) in Multi-acting Receptor-targeted Antipsychotics Treated Schizophrenia Patients
Fute (Flupentixol) combined with MARTAs (Multiple-Acting Receptor Targeted Antipsychotics) drugs has its clinical efficacy toward positive symptoms and might reduce the metabolic syndrome-related factors in patients.
- Conditions
- Schizophrenia; Psychosis, Metabolic Syndrome, Flupentixol, Antipsychotic Agents
- Trial name
- NCT04898270
- Testing
- Flupentixol, Multi-acting receptor-targeted antipsychotics (MARTAs)
- Where
- Taiwan
- Volunteers
- 30 people
- Sponsor
- Taichung Veterans General Hospital
Nausea, Vomiting
Olanzapine Plus Metoclopramide for the Prevention of Opioid-Induced Nausea and Vomiting
The goal of this clinical trial is to evaluate the efficacy and safety of olanzapine plus metoclopramide in preventing opioid-induced nausea and vomiting (OINV) in adult patients with advanced cancer who are initiating strong…
- Trial name
- NCT07208305
- Testing
- Olanzapine, Metoclopramide
- Where
- China
- Volunteers
- 222 people
- Sponsor
- Affiliated Hospital of Qinghai University
Schizophrenia
Efficacy & Safety of SCH 900435 in Schizophrenia (Study P06079)(WITHDRAWN)
The purpose of this study is to assess whether SCH 900435 (Org 25935) 16 mg twice daily is more effective than placebo in the treatment of patients with schizophrenia, using olanzapine 15 mg once daily as active control.
- Trial name
- GUEST (NCT00988728)
- Testing
- SCH 900435 (Org 25935), Olanzapine
- Sponsor
- Merck Sharp & Dohme LLC
Anorexia, Cachexia
Olanzapine for Cancer Related Anorexia-cachexia Syndrome
Cancer anorexia-cachexia syndrome is one of the common conditions in cancer patients. Olanzapine has been demonstrated to reduce chemotherapy-induced anorexia.
- Trial name
- NCT06517199
- Testing
- Olanzapine 2.5 MG, Olanzapine 5 MG
- Where
- 2 sites in Thailand
- Volunteers
- 138 people
- Sponsor
- Mahidol University
Postoperative Nausea and Vomiting
Olanzapine for Nausea After Surgery
Ambulatory surgery is occurring with rapidly increasing frequency as surgical and anesthetic techniques have improved and pressure to reduce health-care costs has increased.
- Trial name
- NCT02755116
- Testing
- Olanzapine
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- Jaime B Hyman
Bipolar Disorder
Depakote Monotherapy, Olanzapine Monotherapy, and Combination Therapy of Depakote Plus Olanzapine in Stable Subjects During the Maintenance Phase of Bipolar Illness
The purpose of this study is to assess the efficacy and safety of continued combination therapy using Depakote plus olanzapine, vs.
- Trial name
- NCT00071253
- Testing
- Divalproex Sodium (Delayed-Release Tablets), Divalproex Sodium (Extended-Release Tablets), Olanzapine
- Where
- 15 sites in United States
- Volunteers
- 180 people
- Sponsor
- Abbott
Schizophrenia
Treatment for First-Episode Schizophrenia
This 3-year study will determine if the antipsychotic medications olanzapine (Zyprexa®) and risperidone (Risperdal®) can help patients with first-episode schizophrenia.
- Trial name
- NCT00000374
- Testing
- Olanzapine, Risperidone
- Where
- 2 sites in United States
- Volunteers
- 125 people
- Sponsor
- Northwell Health
Schizophrenia
Bifeprunox in the Treatment of Schizophrenia
Study of the long-term efficacy and safety of bifeprunox in the treatment of schizophrenia.
- Trial name
- NCT00193713
- Testing
- bifeprunox
- Sponsor
- Solvay Pharmaceuticals
Obesity
Anti-psychotic Medication (New Use) Weight Loss Study
This is a pilot study to determine the safety and efficacy of an investigational product (IHBG-10) on weight change and changes in body composition in subjects who have just started taking (for less than three months) certain…
- Trial name
- NCT01272752
- Testing
- IHBG-10
- Where
- United States
- Sponsor
- Avera McKennan Hospital & University Health Center
Schizophrenia
A Study of the Long-term Safety and Tolerability and the Long-term Effectiveness of Extended-release Oral Paliperidone in Patients Diagnosed With Schizophrenia
The purpose of this study is to evaluate the long-term safety and tolerability and the maintenance of effectiveness of a slow, extended-release oral formulation of paliperidone administered once daily to patients diagnosed with…
- Trial name
- NCT00210769
- Testing
- paliperidone ER Oros
- Volunteers
- 203 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Breast Cancer
Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Chinese Breast Cancer Patients
The Olanzapine Regimen will be superior to the Standard Regimen, as measured by the proportion of patients with Complete Response in the 120 hours following AC chemotherapy.
- Trial name
- NCT03079219
- Testing
- Experimental drug: Aprepitant, Experimental drug: Ondansetron, Experimental drug: Dexamethasone
- Where
- Hong Kong
- Volunteers
- 120 people
- Sponsor
- CCTU
Huntington Disease
Neuroleptic and Huntington Disease Comparison of : Olanzapine, la Tetrabenazine and Tiapride
Huntington's disease (HD) is autosomal dominant neurodegenerative disease, starting in average (with high variability) in the fourth decade.
- Trial name
- NEUROHD (NCT00632645)
- Testing
- Olanzapine, Xenazine, Tiapridal
- Where
- France
- Volunteers
- 180 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Schizophrenia
A Study of ALKS 3831 in Adults With Schizophrenia (The ENLIGHTEN-2 Study)
This study will evaluate weight gain of ALKS 3831 compared to olanzapine in adult subjects with schizophrenia.
- Trial name
- NCT02694328
- Testing
- ALKS 3831, Olanzapine
- Where
- 54 sites in United States, Puerto Rico
- Volunteers
- 561 people
- Sponsor
- Alkermes, Inc.
Schizophrenia, Psychotic Disorders
A Study Comparing the Efficacy of Long-acting Injectable Risperidone and Olanzapine Tablets in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder
The purpose of this study is to document both short-term, as well as long-term efficacy and safety of a long-acting injectable formulation of risperidone, in comparison with olanzapine for the treatment of patients with…
- Trial name
- NCT00236457
- Testing
- risperidone
- Volunteers
- 629 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Borderline Personality Disorder
PET Imaging and Olanzapine Treatment in Borderline Personality Disorder
The overall design of the study is to perform both a PET and MRI scan on objectively identified borderline personality disorder patients, to treat them with olanzapine for 8 weeks, and to then re-scan the patients with PET.
- Trial name
- NCT00275301
- Testing
- olanzapine
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- University of Minnesota